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Abstract
Background: As populations are aging, a growing number of home care clients are frail and use multiple, complex
medications. Combined with the lack of coordination of care this may pose uncontrolled polypharmacy and
potential patient safety risks. The aim of this study was to assess the impact of a care coordination intervention on
medication risks identified in drug regimens of older home care clients over a one-year period.
Methods: Two-arm, parallel, cluster randomized controlled trial with baseline and follow-up assessment at 12
months. The study was conducted in Primary Care in Lohja, Finland: all 5 home care units, the public healthcare
center, and a private community pharmacy. Participants: All consented home care clients aged > 65 years, using at
least one prescription medicine who were assessed at baseline and at 12 months. Intervention: Practical nurses
were trained to make the preliminary medication risk assessment during home visits and report findings to the
coordinating pharmacist. The coordinating pharmacist prepared the cases for the triage meeting with the physician
and home care nurse to decide on further actions. Each patient’s physician made the final decisions on medication
changes needed.
Outcomes were measured as changes in medication risks: use of potentially inappropriate medications and
psychotropics; anticholinergic and serotonergic load; drug-drug interactions.
Results: Participants (n = 129) characteristics: mean age 82.8 years, female 69.8%, mean number of prescription
medicines in use 13.1. The intervention did not show an impact on the medication risks between the original
intervention group and the control group in the intention to treat analysis, but the per protocol analysis indicated
tendency for effectiveness, particularly in optimizing central nervous system medication use. Half (50.0%) of the
participants with a potential need for medication changes, agreed on in the triage meeting, had none of the
medication changes actually implemented.
Conclusion: The care coordination intervention used in this study indicated tendency for effectiveness when
implemented as planned. Even though the outcome of the intervention was not optimal, the value of this paper is
in discussing the real world experiences and challenges of implementing new practices in home care.
Trial registration: ClinicalTrials.gov (NCT02545257). Registered September 9 2015.
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Background
Home care services for older adults are a critically import-
ant part of healthcare [1, 2]. In Finland, home care services
are mostly based on regular, even five-time daily visits by
home care practical nurses (PNs), coordinated by home
care nurses. The allocation of physicians’ time for clients is
limited. As populations are aging, a growing number of
home care clients are frail and use multiple, complex medi-
cations [1, 3]. Combined with the lack of coordination of
care this may pose uncontrolled polypharmacy and poten-
tial patient safety risks [4–6]. E.g., in Finland, the lack of co-
ordination was identified as the major challenge in the
National Medicines Agency’s program to optimize medi-
cine use among older adults [7]. The system-based factors
were found to lead to a situation where no one in the care
team can concentrate on an individual patient’s medica-
tions [4, 7]. These challenges have been addressed in the
current Government Program based Rational Pharmaco-
therapy Action Plan by 2022 with improved coordination
of care as its primary goal [2, 8]. This requires new ways to
organize the care of older adults, e.g. in home care context.
Despite the challenges in the coordination of medication
management processes in primary care, little research has
focused on prospective medication risk management of
older home care clients in this setting. Coordination of care
of home-dwelling older adults has been studied from a nurs-
ing approach with various interventions focusing on disease
management, transitional care and self-management educa-
tion programs [9, 10], but a prospective medication risk
management approach has been out of their scope. Another
widely researched topic has been collaborative medication
review interventions. Even though several recent systematic
reviews and meta-analyses have summarized evidence on
the effectiveness of collaborative medication reviews in vari-
ous healthcare settings [7, 11–13], studies lack descriptions
of the procedures [7]. Furthermore, medication reviews are
shown to be often operationalized as isolated cross-sectional
assessments of patients’ medications without proper integra-
tion and coordination with other patient care procedures,
which has minimized their effectiveness [14]. The aim of this
randomized controlled trial (RCT) was to assess the impact
of enhanced coordination of care on the outcomes of pro-
spective medication risk management of older home care
clients in primary care. The hypothesis was that a care co-
ordination intervention would reduce the number of medi-
cation risks identified in drug regimens of older adults over
a one-year period.
Methods
Design and context
This study was a clustered RCT with a one-year follow-up
period. System-based risk management theory and action
research method were applied to construct the prospective
coordinated medication risk management (CoMM)
procedure used in this RCT [6, 15, 16]. The developed
procedure coordinates existing resources in medication
risk management of older home care clients. One of the
goals was to enhance community pharmacists’ collabor-
ation with home care and enhance their contribution to
prospective medication risk management [6].
This demonstration project was carried out in the mu-
nicipality of Lohja, Finland (48,000 inhabitants and 384
clients receiving regular home care in 2015). The Lohja
Home Care unit presents a typical home care system
within publicly funded healthcare in Finland covering
the entire population [17]. The home care unit is divided
into five service areas, each having a leading nurse,
nurses and practical nurses (PNs) who mostly conduct
home visits [18, 19]. Lohja is a homogenous municipal-
ity, without major regional socioeconomic differences.
The home care service areas are basically equivalent in
characteristics of the clients and standard care provided.
Other units involved in this study are the local health
center and a community pharmacy.
Participants and randomization
Participants were recruited by home care nurses and
PNs between September 2015 and December 2015 [6].
The recruited participants fulfilled the following inclu-
sion criteria: > 65 years old; receives regular home care;
uses at least one prescription medicine; and, a written
informed, voluntary consent to participate, given by the
participant or his/her closest proxy [6].
Participants were cluster randomized to intervention
and control groups by home care service area (Fig. 1)
[6]. The study was considered as open-label. The inter-
vention group (IG) received the intervention (CoMM)
[6] during the first year, while the control group (CG)
received standard home care. After the 12-month
follow-up, the CG received the same intervention.
Standard home care
Standard home care consists of care provided by the
home care units. Based on a client’s needs, it contains
help in daily activities and medicine use. Practical nurses
(PNs) mostly conduct home visits. The frequency of the
visits depends on the client’s needs, varying from weekly
visits to five-times a day visits. Allocation of physicians’
time to home care patients is limited and nurses typic-
ally consult physicians at the health center as needed to
make care decisions, also concerning pharmacotherapy.
PNs or nurses obtain medicines for home care clients
from the private community pharmacy. In most cases,
medicines are dispensed as prepacked sachets by an au-
tomated dose dispensing system (ADD) [20]. Otherwise,
nurses or practical nurses manually dispense the medi-
cines to a doset during their home visits. Some clients
are capable to take their medicines without assistance,
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but usually the nurse or PN must come to their home,
retrieve the medicines from the doset or ADD-
prepacked sachets [20] and give them to the client.
Community pharmacies cooperate with home care units
by dispensing medicines, and assisting in medication
management, e.g., in renewing prescriptions, solving
drug-related problems (DRPs) and training home care
personnel [20].
Intervention
In the CoMM procedure, the core was a triage that cus-
tomized medication reviews according to each home
care clients’ needs and enhanced use of existing re-
sources [6]. First, PNs were trained to screen clinically
significant DRPs, i.e., DRPs needing intervening actions,
during their routine home visits and report their findings
to the home care team consisting of a leading nurse,
nurses and PNs, which forwarded the risk screenings to
the coordinating pharmacist (Fig. 1) [19, 21]. In the DRP
risk screening at home, PNs interviewed their clients by
using the Drug Related Problem Risk Assessment Tool
(DRP-RAT) [21]. The following information was gath-
ered: (1) Basic Client Data, (2) Potential Risks for DRPs
in Medication Use (symptoms potentially suggestive of
Fig. 1 Study flow chart. PN = Practical Nurse, DRP-RAT = Drug-related problem risk assessment tool, DDI = Drug-drug interaction, CMR =
Collaborative Medication review
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ADRs; and medicines potentially harmful or problematic
for adults aged > 65 years), (3) Characteristics of the Cli-
ent’s Care and Adherence (e.g. involvement in one’s
care, health care units recently visited, number of care-
taking physicians), and (4) Recommendations for Ac-
tions to resolve DRPs (e.g. using dose dispensing device,
visiting the personal physician, weekly control visits by a
home care nurse) [21].
PNs also conducted medication reconciliation and
compiled medication lists. Based on the PNsʼ reports
and reconciled medication lists a clinically trained co-
ordinating pharmacist, with the help of the community
pharmacists, identified clients whose medications needed
a physician’s consultation. Electronic medication risk
management tools were utilized in the identification of
clinically significant medication-related risks [6]. If crit-
ical medical concerns were identified, they were advised
to be managed without delay by contacting client’s per-
sonal physician.
Triage meetings and collaborative medication reviews
The physician’s consultations took place in collaborative
triage meetings involving the physician, the coordinating
pharmacist and a home care nurse. It was possible to
agree on actions needed for 50–70 home care clients in
each consultation meeting lasting 2 h [6]. The further ac-
tions usually included more comprehensive, customized
medication reviews that were categorized by modifying
Clyne et al. categorization [6, 22].
The first step was a prescription review in which com-
munity pharmacists identified potential DRPs such as
PIMs, drug-drug interactions (DDIs), serotonergic and
anticholinergic loads from the medication lists by using
computerized tools integrated into the dispensing system
at the community pharmacy. They reported on clients
with clinically significant DRPs to each one’s physician
in a separate brief written report, which was delivered by
nurses [6].
In a more comprehensive medication review, commu-
nity pharmacists used, in addition to medication lists,
medical records and results of the DRP risk assessments
by PNs to make recommendations to solve potential
DRPs (e.g., adjust appropriate doses with renal dysfunc-
tion, adjust use of PIMs potentially inducing adverse
symptoms). Nurses took the written medication review
reports from the pharmacy to each client’s physician.
After that, the community pharmacist involved discussed
the findings and recommendations with the physician on
the phone.
The most comprehensive medication review, i.e. clin-
ical medication review (CMR), was conducted for clients
with complicated medications that included many po-
tential risks, such as inappropriate medicines for older
adults according to Beers Criteria [23], medicines with
inappropriate duration (usually too long duration), in-
appropriate combination of medicines, e.g., clinically sig-
nificant DDIs [24], and symptoms potentially suggestive
of clinically significant ADRs [21] that posed them to a
high risk of harm. This procedure was performed by
community pharmacists specially trained and accredited
for conducting CMRs [25]. In addition to above-
mentioned patient data, they used more extensively
medical records, such as diagnoses, laboratory results,
and medication history for reviewing the medication.
They also made a home visit and interviewed the client
to obtain a comprehensive medication profile [6, 22].
After conducting the review, the community pharmacist
prepared a structured, written case report with recom-
mendations for the physician, and discussed it jointly in
a face-to-face case meeting to decide on actions which
were documented with a follow-up plan.
After the collaborative medication reviews, each cli-
ent’s physician made the final decisions on the changes
to the medication regimens. In some cases, the physician
wanted to meet the home care client and discuss the
changes. In most cases, home care nurses who knew the
clients discussed the changes with them and imple-
mented the changes according to the physician’s orders.
This was a normal routine in the home care context In
Finland, due the limited physician resources. The more
detailed description of the intervention can be found in
the study protocol paper [6].
Clients’ preferences in the intervention
In the risk assessment stage, PNs interviewed the clients
using the DRP-RAT tool, which considers client’s view,
particularly concerns of potential drug-induced adverse
symptoms and poor adherence [21]. Thus, clients’ views
were considered in cases where patient’s condition
allowed their interview, although physicians made the
final clinical decisions. Some clients with severe cogni-
tion impairment were not able to participate in the deci-
sion making related to their medication regimen. In
those cases, decisions were jointly made by the phys-
ician, the nurse and the community pharmacist involved
in the care of the client.
Outcome measures
This study focused on clinically significant medication-
related risks (i.e., DRPs needing intervening actions) as
primary outcomes for assessing the effectiveness of the
intervention. Aspects assessed revolved around poten-
tially inappropriate medications (PIMs), excessive use of
psychotropics, anticholinergic and serotonergic load and
clinically significant drug-drug interactions (DDIs)
(Table 1).
All clinical measures used in this study were adminis-
tered by the PNs and nurses during a separate home
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visit (Table 2). A majority of the applied outcome mea-
sures were in normal clinical use in Lohja Home Care as
indicated in Table 2.
Statistical analyses
Up-to date medication lists gathered from both interven-
tion and standard care group participants at baseline
and at 12-month follow-up point were analyzed for
medication-related risks. All participants who were
assessed at baseline and at 12-month follow-up were in-
cluded in the analyses. Since medication changes pro-
posed in the medication reviews were only partly
implemented, data was analyzed with the intention to
treat (ITT) and per protocol analysis.
1 Baseline analyses
Baseline analyses were conducted to compare the partic-
ipants’ characteristics and the clinically significant medi-
cation risks between the IG and CG participants.
Participants’ characteristics included demographics and
the following clinical outcomes: functional ability (Rava)
[29]; physical performance (The five-times-sit-to-stand
test) [36, 37]; Mini Mental State Examination (MMSE)
[31]; Geriatric Depression Scale − 15 (GDS-15) [32]; The
Mini Nutritional Assessment (MNA) [30]; Urinary
Distress Inventory (UDI-6) [34]; Orthostatic hypotension
(Short test) [33]; and Alcohol Use Disorder Identification
Test, version C (AUDIT-C) [35].
Analyses were performed using a two-sample t-test
for normally distributed variables and by Mann-
Whitney U-test for non-normally distributed variables.
Chi-square or Fisher’s exact test was used for categor-
ical variables.
2 Intention to treat- and per protocol analyses
For the ITT analysis all the participants were in-
cluded in the group in which they were randomly
assigned (IG or CG) regardless of whether medication
changes agreed on were implemented. Per protocol
analysis included only those IG participants that had
at least one of the medication changes actually
implemented.
Descriptive statistics (mean, median or percentages
as appropriate) were used to present the participant
characteristics. The changes within and between
groups in continuous variables were analyzed with re-
peated measures analysis of variance. Dichotomous
outcomes were analyzed by binary logistic regression
using generalized estimating equations to account for
the correlation between the repeated measurements.
Table 1 Clinically significant medication-related risks that were assessed as outcomes in this study
Outcome Aspects assessed
Number of all medications The total number of regular and pro re nata (when required) medications that have
been prescribed (i.e. prescribed medication that is scheduled), over-the-counter and
herbal products are not included
Use of harmful medications Included Beers Criteria medications [23], psychotropic medications and
anticholinergic medications according to Puustinen et al. 2012 [26].
Use of Beers Criteria [23] medications Potentially inappropriate medicines for older adults according to Beers Criteria [23].
Use of CNS medications Opioids (ATC code N01AH, N02A, N02BE51, R05DA, R05FA); anticholinergic drugs
according to Puustinen et al. 2012 [26], antiepileptics (ATC code N03A); BZDs and
related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70,
M05AA51, N06CA01, N02BA71); antidepressants (ATC codes N06A, N06CA);
antipsychotics (ATC codes N05A, N06CA01).
Use of Psychotropic medications
Proportion of study participants using > 3
psychotropic medications, n (%)
BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA,
C01DA70, M05AA51, N06CA01, N02BA71); antidepressants (ATC codes N06A,
N06CA); antipsychotics (ATC codes N05A, N06CA01) [26]
Proportion of study participants using > 2
serotonergic medications, n (%)
Serotonergic medications according to Salko database [27].
Proportion of study participants using
anticholinergic medications, n (%)
Anticholinergic medicines according to Puustinen et al. 2012 [26].
Proportion of study participants using
antipsychotics, n (%)
ATC codes N05A, N06CA01
BZD users, n (%) BZDs and related drugs (ATC codes N05BA, N05CD, N03AE01, N05CF, A03CA,
C01DA70, M05AA51, N06CA01, N02BA71) [26]
Opioid users, n (%) ATC codes N01AH, N02A, N02BE51, R05DA, R05FA
PPI user, n (%) ATC A02BC
Prevalence of clinically significant drug-drug
interactions (SFINX class D) [24]
Interactions that should be avoided or used with caution [24].
CNS central nervous system, ATC The Anatomical Therapeutic Chemical classification system, WHO 2018 [28], BZD benzodiazepine, PPI proton-pump inhibitor
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Results are expressed using odds ratios (OR) with
95% confidence intervals (CI). ITT analyses were ad-
justed for functional ability and the use of antiepilep-
tic medications, and per protocol analyses were
adjusted for functional ability, use of central nervous
system medications (CNS-medications), GDS-15 and
MNA due to group differences at the baseline. In the
longitudinal analysis were included participants with
baseline measurement and at least one follow-up
measurement at 12-month follow-up point. Two-sided
Table 2 Baseline Characteristics of Participants (including all participants assessed at baseline and at 12-month follow-up)
N Total Intervention Group (N = 65) Control Group (N = 64) pc
Female, n (%) 129 90 (69.8) 44 (67.7) 46 (71.9) 0.61
Mean age; years, (SD), range 129 82.8 (7.1), 65–96 81.6 (7.1), 65–95 84.0 (6.8), 67–96 0.05
Age group, n (%) 129 0.08
65–69 8 (6.2) 5 (7.7) 3 (4.7)
70–74 9 (7.0) 5 (7.7) 4 (6.3)
75–79 17 (13.2) 13 (20.0) 4 (6.3)
80–84 41 (31.8) 21 (32.3) 20 (31.3)
85- 54 (41.9) 21 (32.3) 33 (51.6)
Living alone, n (%) 126 104 (80.6) 53 (84.1) 51 (81.0) 0.64
Rava indexa,b [29], mean (SD) 128 1.98 (0.61) 2.19 (0.63) 1.77 (0.51) < 0.001
MD 1.83 2.08 1.59
MNA Screeningb [30] 127 0.14
Normal nutritional status (12–14 points), n (%) 65 (51.2) 30 (46.9) 35 (55.6)
At risk of malnutrition (8–11 points), n (%) 54 (42.5) 32 (50.0) 22 (34.9)
Malnourished (0–7 points), n (%) 8 (6.3) 2 (3.1) 6 (9.5)
MMSEb [31] 126 0.44
25–30 (no cognitive impairment), n (%) 44 (34.9) 19 (30.7) 25 (39.1)
18–24 (mild cognitive impairment), n (%) 70 (55.6) 38 (61.3) 32 (50.0)
0–17 (severe cognitive impairment), n (%) 12 (9.5) 5 (8.1) 7 (10.9)
GDS-15b [32] > 6 (suggestive of depression), n (%) 127 39 (30.7) 21 (33.3) 18 (28.1) 0.52
Proportion with orthostatic hypotension [33], n (%) 106 24 (22.6) 14 (29.2) 10 (17.2) 0.14
UDI-6 [34], mean (SD) 126 3.2 (4.0) 3.3 (4.4) 3.2 (3.6) 0.92
MD 2.0 2.0 2.0
AUDIT-C [35], mean (SD) 128 0.9 (1.7) 1.2 (1.9) 0.7 (1.5) 0.59
MD 0.0 0.0 0.0
The five-times-sit-to-stand testb [36, 37].
Participants with inability to complete the test, n (%)
128 52 (40.6) 32 (50.0) 20 (31.3) 0.03
Medication use 129
Number of regular medications, mean (SD) 10.1 (3.3) 10.4 (3.3) 9.8 (3.2) 0.25
Number of pro re nata medications, mean (SD) 3.0 (1.8) 3.1 (1.7) 2.9 (1.8) 0.54
Number of all medications, mean (SD) 13.1 (4.1) 13.5 (3.9) 12.7 (4.3) 0.25
Number of all medication, classified 0.53
1–6, n (%) 5 (3.9) 1 (1.5) 4 (6.3)
7–9, n (%) 16 (12.4) 7 (10.8) 9 (14.1)
10–15, n (%) 76 (58.9) 40 (61.5) 36 (56.3)
16+, n (%) 32 (24.8) 17 (26.2) 15 (23.4)
SD standard deviation, MD median, MNA The Mini Nutritional Assessment, MMSE Mini Mental State Examination, GDS-15 Geriatric Depression Scale, UDI-6 (Urinary
Distress Inventory), AUDIT-C (Alcohol Use Disorder Identification Test, version C)
aRava index describes the need of help based on functional ability (scale 1.29–4.03; results 1.50–1.99 mean need for regular help); bMeasure used in usual clinical
practice in Lohja Home Care; cDifferences between the groups were tested with Chi-squared test or Fischer exact test in categorical variables and with Mann-
Whitney test or two-sample t-test in continuous variables
Toivo et al. BMC Geriatrics          (2019) 19:332 Page 6 of 13
statistical tests with a 5% level of significance were
used.
Results
Study participants and attrition rate
Of 384 eligible home care clients, 191 (49.7%) clients or
their proxies provided written consent to participate (Fig.
1). The IG included 104 participants, of which three
dropped out before baseline data gathering. The CG in-
cluded 87 study participants. There was a remarkable at-
trition rate, with 59 participants (31.4%) lost to follow-up
at 12months. In the IG, attrition rate was 35.6% (n = 36)
and in the CG 26.4% (n = 23) (p = 0.18) (Fig. 1). Drop-out
analysis between the IG and CG participants did not show
statistically significant differences in baseline characteris-
tics (data not shown). Number of participants with base-
line and 12-months follow-up data available, included into
the analyses, was 129.
At baseline, the characteristics of the participants (n =
129) in the IG and CG did not differ, despite differences
in functional ability (Rava) (p = 0.01) and the use of anti-
epileptic medications (ATC code N03A) (p = 0.003),
which were adjusted in the ITT analysis. The mean age
of the participants (n = 129) was 82.8 years (SD 7.05),
82.5% (n = 104), were living alone and 69.8% (n = 90)
were women (Table 2). The mean number of prescrip-
tion medications (regular and pro re nata, i.e. when re-
quired) was 13.5 (SD 3.87) in the IG compared with 12.7
(SD 4.30) in the CG (p = 0.25).
The baseline characteristics of the IG (n = 27) and CG
participants (n = 64), included in the per protocol ana-
lysis, differed in functional ability (Rava) (p = 0.006), use
of CNS-medication (p = 0.02), GDS-15 (p = 0.03), and
MNA (p = 0.005), which were adjusted.
Use of PIMs at baseline
Use of PIMs, excessive use of psychotropics, and high
anticholinergic and serotonergic load was common in
both groups at baseline (Table 3). Prevalence of Beers
Criteria [23] medication use was 93.9% in IG and 90.6%
in CG (p = 0.53); anticholinergic use was 27.7% in IG
and 18.8% in CG (p = 0.23); > 3 psychotropics use was
20.0% in IG and 9.4% in CG (p = 0.09) (Table 3). The
most commonly used Beers Criteria medications were
proton pump inhibitors (PPIs), when used for longer
than 2months without precise indication: this was the
case for 50.4% (n = 60) of the Beers Criteria medication
users (n = 119).
Effect of the intervention (CoMM) on the use of PIMs (ITT
analyses)
No clinically significant medication-related risks needing
collaborative medication review were found for 45.5%
(n = 45) of the 99 IG participants who had DRP-RAT
assessment available (Fig. 1). Of the remaining 54.5%
(n = 54), prescription review was needed in 29.6% (n =
16), medication review in 63.0% (n = 34), and compre-
hensive medication review in 7.4% (n = 4) of the cases.
Mean number of all medications in use increased in
both groups over the 12-month follow-up period: in IG
from 13.5 to 14.1 (adjusted mean change 0.77 95% CI
0.05–1.48; p = 0.04) and in CG from 12.7 to 13.0 (ad-
justed mean change 0.52 95% CI -0.37-1.41; p = 0.25)
(Table 3). The prevalence of PIM use remained mainly
constant in both groups. No significant changes
(p < 0.05) were found in any selected medication-related
outcomes between the IG and CG in the ITT analyses
(Table 3).
Per protocol analyses
Per protocol analysis compared IG participants with at
least one implemented medication change (n = 27) with
CG participants (n = 64) (Table 4). No significant differ-
ences (p < 0.05) were found in medication-related out-
comes between the IG per protocol (IGpp) and CG over
the 12-month follow-up period (Table 4). However, a
tendency for a decrease was found in the use of central
nervous system (CNS) medications between the groups
(p = 0.08): in IGpp a decrease of 18.5 percentage points
was observed (adjusted OR 0.15 95% CI 0.03–0.80),
compared to a decrease of 3.1 percentage points (ad-
justed OR 0.81 95% CI 0.37–1.77) in CG.
Analyses within the per protocol group (n = 27)
In the analyses within the IGpp, in addition to a decrease
in CNS use (from 92.6 to 74.1%; adjusted OR 0.15, 95%
CI 0.03–0.80; p = 0.03), the use of benzodiazepines
(BZDs) decreased from 55.6 to 37.0% (adjusted OR 0.43,
95% CI 0.21–0.91; p = 0.03). A tendency for a decrease
within the IGpp (p < 0.10) was shown in the following
outcomes: proportion of persons using > 3 psychotropic
medications decreased from 18.5 to 7.4% (p = 0.07); and
opioid use decreased from 40.7 to 26.0% (p = 0.09)
(Table 4).
Discussion
The intervention did not show an impact on the use of
PIMs between the original intervention group and the
control group in the intention to treat analysis, but the
per protocol analysis indicated tendency for effective-
ness, particularly in optimizing CNS medication (espe-
cially in BZD) use during a 12-month follow-up. As the
original IG included many home care clients whose
medication changes were not actually implemented as
proposed (50% of the intervention group participants),
the intervention was incomplete for them. Thus, per
protocol analysis is a better predictor of the effectiveness
of the coordinated home care model than a comparison
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between the original intervention group and the control
group.
High prevalence of PIM use
Our baseline findings demonstrate a high prevalence of
PIM use. Particularly, the prevalence of potentially inappro-
priate psychotropic medication use was high (58.1%, n = 75)
in the entire study population (IG and CG, n = 129) in-
cluded in the intention to treat analysis. Most common was
potentially inappropriate BZD use (41.1%) and antidepres-
sant use (36.4%). National register-based data shows that
long-term use of BZDs is the major PIM-related concern in
Finland, particularly the use of temazepam [38]. A more re-
cent study indicates a declining trend in the long-term
BZD use over the last years (2006–2014), but the long-term
BZD use has remained constant among the older adults
[39]. The decline has not been uniform between the sub-
stances: the long-term use of clonazepam and zolpidem has
Table 3 Outcomes describing potentially inappropriate medicine use at baseline and after 12 months in the intervention and
control groups and significance of changes within and between the groups during the follow-up
Medication in use Intervention group (N = 65) Control group (N = 64)
Baseline At 12
months
Adjusted mean
change [95% CI]
or adjusted OR
(95% CI) for change
p for
change
Baseline At 12
months
Adjusted mean
change [95% CI]
or adjusted OR
(95% CI) for change
p for
change
Ph for the
difference
in change
between
the groups
Number of all medications,
mean (SD)
13.5
(3.9)
14.1
(3.8)
0.77 [0.05–1.48] 0.04 12.7
(4.30)
12.95
(4.03)
0.52 [−0.37–1.41] 0.25 0.59
Harmful medicationa
user, n (%)
56
(86.2)
57
(87.7)
1.15 (0.63–2.10) 0.66 51
(79.7)
51
(79.7)
1.00 (0.63–1.60) 1.00 0.73
Beers Criteria [23] medication user,
n (%)
61
(93.9)
63
(96.9)
2.12 (0.34–13.2) 0.42 58
(90.6)
57
(89.1)
0.84 (0.39–1.82) 0.66 0.36
Psychotropic medicationb user, n
(%)
43
(66.2)
45
(69.2)
1.15 (0.78–1.72) 0.48 32
(50.0)
30
(46.9)
0.88 (0.62–1.25) 0.48 0.32
Anticholinergic medicationc user, n
(%)
18
(27.7)
17
(26.2)
0.92 (0.58–1.42) 0.74 12
(18.8)
12
(18.8)
1.00 (0.75–1.33) 1.00 0.77
CNS medicationd user,
n (%)
56
(86.2)
53
(81.5)
0.69 (0.34–1.41) 0.31 45
(70.3)
43
(67.2)
0.86 (0.49–1.50) 0.59 0.64
Therapeutic duplication
Proportion using > 3
psychotropic medicationsb, n (%)
13
(20.0)
12
(18.5)
0.81 (0.53–1.22) 0.31 6 (9.4) 5 (7.8) 0.82 (0.41–1.62) 0.57 0.97
Proportion using > 2
serotonergic medications [27], n
(%)
13
(20.0)
16
(24.6)
1.35 (0.88–2.06) 0.17 5 (7.8) 7 (10.9) 1.47 (0.69–3.16) 0.32 0.84
Use of special ATC classes
Antipsychotics userse,
n (%)
13
(20.0)
15
(23.1)
1.20 (0.72–2.01) 0.48 7 (10.9) 7 (10.9) 1.00 (0.64–1.57) 1.00 0.59
BZDf users, n (%) 32
(49.2)
30
(46.2)
0.88 (0.62–1.25) 0.48 21
(32.8)
20
(31.3)
0.93 (0.64–1.35) 0.70 0.83
Opioidg users, n (%) 18
(27.7)
17
(26.2)
0.92 (0.55–1.55) 0.76 22
(34.4)
20
(31.3)
0.87 (0.58–1.29) 0.48 0.85
PPI (ATC A02BC) user,
n (%)
30
(46.2)
30
(46.2)
1.00 (0.78–1.29) 1.00 30
(46.9)
33
(51.6)
1.21 (0.92–1.59) 0.17 0.31
Drug-drug interactions (DDI)
Clinically significant DDI
(class D) [24], n (%)
7 (10.8) 6 (9.2) 0.84 (0.39–1.79) 0.65 1 (1.6) 0 (0) NA 0.32i NA
SD standard deviation, OR Odds ratio, CI Confidence interval, CNS central nervous system, BZD benzodiazepine, PPI proton-pump inhibitor medicine
a.Harmful medications Included 1) Beers Criteria medications [23], 2) b.psychotropic medications [26] (Included fBZDs and related drugs: ATC codes N05BA, N05CD,
N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71; Antidepressants: ATC codes N06A, N06CA; eAntipsychotics: ATC codes N05A, N06CA01); 3) c
Anticholinergic medications [26]: ATC codes: N04A, N05AA01, N05AA02, N05AB01, N05AB02, N05AB03, N05AB04, N05 AC01, N05 AC02, N05AF01, N05AF03,
N05AF05, N05BB01, N06AA04, N06AA06, N06AA09, N06AA12, N02AG, A03AA, A03AB, A03AX03, A03B, A03CA, A03CB31, A03DA, A03FA01, A04AD01, A04AD12,
C01BA01, C01BA03, C01BA51, C01BA71, R03BB, M03B, G04BD, S01FA, R01BA01, R01BA51, R06AB01, R06AE03, R06AE53). If the medication appeared in two or
more criteria, they were considered only once
dCNS medications: gOpioids (ATC codes N01AH, N02A, N02BE51, R05DA, R05FA), canticholinergics [26]; antiepileptics (ATC N03A); fBZDs and related drugs (ATC
codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71); Antidepressants (ATC codes N06A, N06CA); eAntipsychotics (ATC codes
N05A, N06CA01)
hAdjusted for functional ability Rava and the use of antiepileptic medications (ATC code N03A).i McNemar test due to zero frequencies
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even increased [39]. These findings indicate an urgent need
for effective deprescribing interventions that should be ac-
tively promoted to make them part of the routine clinical
practice. There are recent promising results of successfully
reducing long-term BZD use in older adults by
community-based interventions in primary care [40, 41].
Inappropriate use of antipsychotics (APs) is another
major concern in geriatric pharmacotherapy which can
also be seen in our data (baseline users: 15.5%, n = 20).
APs are usually prescribed for behavioral disorders with
dementia but the use may even continue for years with-
out proper follow-ups [42]. International criteria, e.g.
Beers Criteria, have updated their recommendations on
the use of APs in recent years: use should be avoided
unless nonpharmacological options have failed or are
not possible and the person is threatening substantial
Table 4 Outcomes describing potentially inappropriate medicine use at baseline and after 12 months in the per protocol
intervention group and control groups and significance of changes within and between the groups during the follow-up
Medication in use Intervention group (N = 27) Control group (N = 64)
Baseline At 12
months
Adjusted mean
change [95% CI]
or adjusted OR
(95% CI) for change
p for
change
Baseline At 12
months
Adjusted mean
change [95% CI]
or adjusted OR
(95% CI) for change
p for
change
Pi for the
difference
in change
between
the groups
Number of all medications,
mean (SD)
14.0
(3.9)
13.3
(3.3)
−0.02 [−1.24–1.20] 0.97 12.7
(4.3)
13.0
(4.0)
0.38 [−0.59–1.36] 0.44 0.46
Harmful medicationa
user, n (%)
23
(85.2)
22
(81.5)
0.61 (0.13–2.88) 0.54 51
(79.7)
51
(79.7)
1.00 (0.50–2.02) 1.00 0.58
Beers Criteria [23]
medication
user, n (%)
26
(96.3)
25
(92.6)
0.42 (0.02–7.52) 0.56 58
(90.6)
57
(89.1)
0.82 (0.34–1.95) 0.65 0.67
Psychotropic medicationb user, n
(%)
21
(77.8)
19
(70.4)
0.47 (0.04–5.24) 0.54 32
(50.0)
30
(46.9)
0.56 (0.11–2.72) 0.47 0.90
Anticholinergic medicationc user, n
(%)
8 (29.6) 5 (18.5) 0.62 (0.25–1.56) 0.31 12
(18.8)
12
(18.8)
1.00 (0.72–1.39) 1.00 0.34
CNS medicationd
user, n (%)
25
(92.6)
20
(74.1)
0.15 (0.03–0.80) 0.03 45
(70.3)
43
(67.2)
0.81 (0.37–1.77) 0.59 0.08
Therapeutic duplication
Proportion using > 3
psychotropic medicationsb, n (%)
5 (18.5) 2 (7.4) 0.35 (0.11–1.10) 0.07 6 (9.4) 5 (7.8) 0.82 (0.42–1.62) 0.56 0.21
Proportion using > 2
serotonergic medications [27], n
(%)
6 (22.2) 7 (26.0) 1.28 (0.56–2.92) 0.56 5 (7.8) 7 (10.9) 1.49 (0.68–3.26) 0.32 0.79
Use of special ATC classes
Antipsychotics
userse, n (%)
6 (22.2) 4 (14.8) 0.59 (0.20–1.69) 0.32 7 (10.9) 7 (10.9) 1.00 (0.61–1.65) 1.00 0.37
BZDf users, n (%) 15
(55.6)
10
(37.0)
0.43 (0.21–0.91) 0.03 21
(32.8)
20
(31.3)
0.89 (0.47–1.67) 0.71 0.15
Opioidg users, n (%) 11
(40.7)
7 (26.0) 0.49 (0.21–1.11) 0.09 22
(34.4)
20
(31.3)
0.86 (0.57–1.30) 0.47 0.23
PPI (ATC A02BC)
user, n (%)
13
(48.2)
13
(48.2)
1.00 (0.62–1.61) 1.00 30
(46.9)
33
(51.6)
1.23 (0.91–1.66) 0.18 0.47
Drug-drug
interactions (DDI)
Clinically significant
DDI (class D) [24], n (%)
2 (7.4) 2 (7.4) 1.00 (0.21–4.67) 1.00 1 (1.6) 0 (0.0) NA 0.32h NA
SD standard deviation, OR Odds ratio, CI Confidence interval, CNS central nervous system, BZD benzodiazepine, PPI proton-pump inhibitor, NA not available
a Harmful medications Included 1) Beers Criteria medications [23], 2) b psychotropic medications [26] (Included fBZDs and related drugs: ATC codes N05BA, N05CD,
N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71; Antidepressants: ATC codes N06A, N06CA; eAntipsychotics: ATC codes N05A, N06CA01); 3) c
Anticholinergic medications [26]: ATC codes: N04A, N05AA01, N05AA02, N05AB01, N05AB02, N05AB03, N05AB04, N05 AC01, N05 AC02, N05AF01, N05AF03,
N05AF05, N05BB01, N06AA04, N06AA06, N06AA09, N06AA12, N02AG, A03AA, A03AB, A03AX03, A03B, A03CA, A03CB31, A03DA, A03FA01, A04AD01, A04AD12,
C01BA01, C01BA03, C01BA51, C01BA71, R03BB, M03B, G04BD, S01FA, R01BA01, R01BA51, R06AB01, R06AE03, R06AE53). If the medication appeared in two or
more criteria, they were considered only once
d CNS medications: gOpioids (ATC codes N01AH, N02A, N02BE51, R05DA, R05FA), canticholinergics [26]; antiepileptics (ATC N03A); fBZDs and related drugs (ATC
codes N05BA, N05CD, N03AE01, N05CF, A03CA, C01DA70, M05AA51, N06CA01, N02BA71); Antidepressants (ATC codes N06A, N06CA); eAntipsychotics (ATC codes
N05A, N06CA01). hMcNemar test due to zero frequencies. iAdjusted for functional ability Rava, CNS medications, GDS-15, MNA
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harm to self or others [23]. However, Finnish guidelines
are not as strict concerning AP use in older adults as the
most recent international guidelines [43]. This may
partly explain their wide use among older outpatients
and inpatients in Finland [42]. It would be important to
reconsider our domestic guidelines and care practices to
meet current international standards in AP use.
Another contributing factor to excessive use of anti-
psychotics in older adults is culture of care [44, 45]. Our
experience in Lohja Home Care was that some of the
physicians and nurses were reluctant to actually stop the
AP treatment even though the potential need for depre-
scribing was agreed on in the triage meeting. As previ-
ous studies have shown, this may be due to concern
about stopping medications started and prescribed by
other physicians, limited knowledge about how to stop
APs, and concern about a relapse of behavioral disorders
[45–47]. Further research is needed to better understand
these systems-based factors influencing AP use that can
lead to unnecessary and harmful long-term medications.
Triage
The core of the intervention in this study was triage
meetings that proved to be a feasible method for cus-
tomizing comprehensiveness of collaborative medication
reviews (CMRs) for older home care clients according to
their clinical needs while minimizing physician’s time re-
quired [6]. Of the older home care clients, 45.5% had no
need for more comprehensive medication reviews. The
triage enabled focusing on clients with clinically signifi-
cant DRPs instead of comprehensively reviewing medi-
cations of all clients, as has been the case in many
previous studies [7].
Implementation of the intervention
We experienced challenges in implementing the new pro-
cedure. This was also seen in the analysis of the effective-
ness of the intervention. Physicians’ limited resources,
partly reluctant attitudes and weak engagement to the
new, more collaborative medication management practice
were evaluated as the main contributing factors for inter-
vention not being implemented. Some physicians were re-
luctant and did not approve and implement any of the
recommended clinically significant medication changes.
Thus, these factors affecting medicines optimization need
further investigation. This trial represents real world and
has features of pragmatic trials, which frequently include
complex interventions, involving the skills and experience
of various health care providers to deliver the intervention
[48]. Our experience is that implementation of this kind
of new coordinated procedure requires long-term and
goal-oriented commitment of all healthcare providers in-
volved to break organizational barriers and change work-
ing behaviors and patterns. Educational needs in both
geriatric pharmacotherapy and understanding system-
based medication risk management were identified in all
participating health care providers and community phar-
macists [6]. The most striking competence gap observed
relates to deprescribing. Thus, a better deprescribing
protocol needs to be used in future studies.
Strength and limitations of the methods
Our study design and randomization strategy worked well.
At baseline, the characteristics of the participants in the
IG and the CG were similar, despite functional ability
(Rava) and use of antiepileptics, which were adjusted in
the ITT-analyses. We used cluster randomization to avoid
contamination related to nurses and PNs. Contamination
related to community pharmacists and physicians was not
considered, since these professionals did not have regular
encounters with the home care clients. Clustering by ser-
vice area was not accounted in the data analysis.
We selected such outcome measures and follow-up
periods that have been proven appropriate in previous
studies [7, 14, 49]. A 12-month follow up period has
shown to be long enough to implement medication
changes, demonstrate potential changes in study partici-
pants’ health outcomes and sustainability of changes
made in their medications. Selected measures were con-
gruent with recent studies proposing core outcome mea-
sures for trials aiming to improve appropriate
medication use in older adults [50, 51]. Our goal in the
future study is to investigate whether there is an associ-
ation between the intermediate measures used in this
study (medication risks) and improved health/function/
cognition outcomes.
A limitation of this study is a relatively small sample
size, which may have affected the weak effectiveness of
the intervention. Half of the eligible residents did not
provide written consent to participate. High workload of
the recruiting nursing staff, as well as frail and multi-
morbid home care clients were evaluated as main con-
tributing factors. It was also contributed by the high
attrition rate during the first study year, due to high age
and multiple morbidities of the participants. In future
studies with multi-morbid and frail older adults, these
methodological issues crucially influencing the power of
the study needs to be considered better. The same has
been observed in other studies with multi-morbid older
adults [52].
We included in the analysis only participants with
baseline and 12-month follow-up data available [53].
Poor implementation of recommended medication
changes was the rationale for conducting per protocol
analyses, including only participants with at least one
clinically significant medication change actually imple-
mented. As we were able to show a tendency for effect-
iveness in the per protocol analysis, it would be
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important to repeat the intervention with larger study
populations to confirm the findings.
This demonstration study was carried out by involving
in the intervention only one community pharmacy oper-
ating in Lohja. This strategy was chosen to keep the
study design simple as adding more community pharma-
cies to the study would have increased risk of bias. It
would be important to repeat the intervention in the
home care of other municipalities and involve other
community pharmacies in future research.
Practical implications
This was a demonstration study showing preliminary and
promising positive results. The procedure can be trans-
ferred to other home care units and adopted to their local
circumstances. The procedure could be particularly de-
signed to reduce CNS use in older adults as it is among
the major problems in geriatric pharmacotherapy in
Finland [38, 39, 42]. Further studies are needed on care
culture and other contributing factors to high prevalence
of PIM use and other risks for clinically significant DRPs
identified in this study. Particularly, physicians’ reluctance
to implement recommended medication changes in the
cases with inappropriate polypharmacy, and relationship
between inappropriate medication use and medication er-
rors need further investigation.
Conclusion
The care coordination intervention used in this study in-
dicated tendency for effectiveness when implemented as
planned, particularly in optimizing CNS medication use
during a 12-month follow-up. This study demonstrates
the challenges to overcome when trying to change clin-
ical practice and improve coordination between units in-
volved in medication management of home care clients.
Even though the outcomes of the intervention were not
optimal, the value of this paper is in discussing the real
world experiences and challenges of implementing new
practices in home care. This may help to inform future
interventions and improve medication use for older
persons.
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